SCHEMBL6557580

SCHEMBL6557580

O=c1c(CO)coc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 1.00
CYP11B1 P15538 3/20 0.59
CYP11B2 P19099 3/20 0.59
CYP17A1 P05093 1/20 0.59
CYP19A1 P11511 1/20 0.59
MAOA P21397 2/20 0.55
SIGMAR1 Q99720 2/20 0.55
PTPN1 P18031 1/20 0.53
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
HTR1A P08908 1/20 0.48
ADORA2B P29275 1/20 0.47
MIF P14174 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456742 0.89 MAOB (0.79) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL20378369 0.86 MAOB (0.76) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL12655257 0.85 MAOB (0.73) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL6511946 0.84 MAOB (0.71) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL9075843 0.83 MAOB (0.71) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL292868 0.83 MAOB (0.71) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL8359747 0.83 MAOB (0.71) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL1305435 0.81 MAOB (0.68) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL11869359 0.81 MAOB (0.68) MAOBCYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL536553 0.80 MAOB (0.67) MAOBCYP11B1CYP11B2CYP17A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115636808-B Chromone-benzoyl hydrazone alpha-glucosidase inhibitor and preparation method and application thereof 贵州医科大学附属医院 2023-10-17 CN claimed
CN-115636808-A Chromone-benzoyl hydrazone alpha-glucosidase inhibitor as well as preparation method and application thereof 贵州医科大学附属医院 2023-01-24 CN claimed
EP-1115717-B1 3-(HYDROXYMETHYL)CHROMEN-4-ONES AND PROCESS FOR THEIR PREPARATION FERRER INT (ES) 2004-03-10 EP claimed
US-6348605-B1 TREATING 2-(HYDROXY)CHROMAN-4-ONES WITH FORMALDEHYDE AND BASIC CATALYST FOLLOWED BY DEHYDRATION IN ACID MEDIUM FERRER INTERNACIONAL, S.A. (ES) 2002-02-19 US claimed
EP-1115717-A1 3-(HYDROXYMETHYL)CHROMEN-4-ONES AND PROCESS FOR THEIR PREPARATION FERRER INTERNACIONAL, S.A. (ES) 2001-07-18 EP claimed
WO-2000017183-A1 3-(HYDROXYMETHYL)CHROMEN-4-ONES AND PROCESS FOR PREPARING FERRER INTERNACIONAL, S.A. (ES) 2000-03-30 WO claimed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
CN-115636808-B Chromone-benzoyl hydrazone alpha-glucosidase inhibitor and preparation method and application thereof 贵州医科大学附属医院 2023-10-17 CN disclosed
CN-115636808-A Chromone-benzoyl hydrazone alpha-glucosidase inhibitor as well as preparation method and application thereof 贵州医科大学附属医院 2023-01-24 CN disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 EP disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 WO disclosed
WO-1997028157-A1 NOVEL PIPERIDINE DERIVATIVES 4-SUBSTITUTED BY AN IMIDAZOLIDIN-2-ON-1-YL-ETHYL, TETRAHYDROPYRIMIDIN-2-ON-1-YL-ETHYL AND 1,3-DIAZEPIN-2-ON-1-YL-ETHYL GROUP, AND USE THEREOF AS α2-ADRENERGIC RECEPTOR ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 1997-08-07 WO disclosed
US-4327091-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1982-04-27 US disclosed
US-4213980-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1980-07-22 US disclosed
US-4098799-A ANTIALLERGENS, HYPERACIDITY WARNER-LAMBERT COMPANY (US) 1978-07-04 US disclosed
US-4008252-A ANTIALLERGENS, ANTIHYPERACIDITY WARNER-LAMBERT COMPANY (US) 1977-02-15 US disclosed
US-3937837-A SUBSTITUTED CHROMONE-3-CARBONITRILES, CARBOXAMIDES AND CARBOXYLIC ACIDS USEFUL FOR PREVENTING ASTHMATIC SYMPTOMS WARNER-LAMBERT COMPANY (US) 1976-02-10 US disclosed
US-3887584-A 3-(Hydroxymethyl)chromones WARNER LAMBERT CO 1975-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS MAOB 730/4885CYP11B1 43/4885CYP11B2 50/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS MAOB 730/4885CYP11B1 43/4885CYP11B2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.